» Authors » Abdelrahman H Elsayed

Abdelrahman H Elsayed

Explore the profile of Abdelrahman H Elsayed including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 217
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
H Elsayed A, Cao X, Marrero R, Nguyen N, Wu H, Ni Y, et al.
NPJ Precis Oncol . 2024 Aug; 8(1):168. PMID: 39090192
In this study, we leveraged machine-learning tools by evaluating expression of genes of pharmacological relevance to standard-AML chemotherapy (ara-C/daunorubicin/etoposide) in a discovery-cohort of pediatric AML patients (N = 163; NCT00136084...
2.
Marrero R, Wu H, Cao X, Parcha P, H Elsayed A, Inaba H, et al.
Clin Cancer Res . 2024 Jul; 30(19):4388-4396. PMID: 39078289
Purpose: Cytarabine (also known as ara-C) has been the backbone of acute myeloid leukemia (AML) chemotherapy for more than five decades. Recent pharmacogenomics-based 10-SNP ara-C (ACS10) scores showed low ACS10...
3.
Elzeneini M, Mahmoud A, H Elsayed A, Taha Y, Meece L, Al-Ani M, et al.
Am Heart J Plus . 2024 Apr; 2:100006. PMID: 38560584
Study Objective: Early bleeding is a common source of morbidity associated with left ventricular assist device (LVAD) implantation. Our objective was to identify potential predictors of peri-implant bleeding. Methods: We...
4.
Gao Q, Ryan S, Iacobucci I, Ghate P, Cranston R, Schwab C, et al.
Blood . 2023 May; 142(8):711-723. PMID: 37216686
Intrachromosomal amplification of chromosome 21 defines a subtype of high-risk childhood acute lymphoblastic leukemia (iAMP21-ALL) characterized by copy number changes and complex rearrangements of chromosome 21. The genomic basis of...
5.
Larkin T, Kashif R, H Elsayed A, Greer B, Mangrola K, Rafiee R, et al.
JCO Precis Oncol . 2023 Mar; 7:e2200580. PMID: 36952646
Purpose: Acute lymphoblastic leukemia (ALL) is the most prevalent cause of childhood cancer and requires a long course of therapy consisting of three primary phases with interval intensification blocks. Although...
6.
Cao X, H Elsayed A, Pounds S
Methods Mol Biol . 2023 Mar; 2629:349-373. PMID: 36929085
Pediatric cancer multi-omics is a uniquely rewarding and challenging domain of biomedical research. Public generosity bestows an abundance of resources for the study of extremely rare diseases; this unique dynamic...
7.
Marrero R, Cao X, Wu H, H Elsayed A, Klco J, Ribeiro R, et al.
Blood Adv . 2023 Jan; 7(11):2538-2550. PMID: 36689724
Cytarabine arabinoside (Ara-C) has been the cornerstone of acute myeloid leukemia (AML) chemotherapy for decades. After cellular uptake, it is phosphorylated into its active triphosphate form (Ara-CTP), which primarily exerts...
8.
Nguyen N, Rafiee R, Tagmount A, Sobh A, Loguinov A, de Jesus Sosa A, et al.
Blood Adv . 2022 Sep; 7(9):1769-1783. PMID: 36111891
Etoposide is used to treat a wide range of malignant cancers, including acute myeloid leukemia (AML) in children. Despite the use of intensive chemotherapeutic regimens containing etoposide, a significant proportion...
9.
Brady S, Roberts K, Gu Z, Shi L, Pounds S, Pei D, et al.
Nat Genet . 2022 Sep; 54(9):1376-1389. PMID: 36050548
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using whole-genome, exome and transcriptome sequencing of 2,754 childhood patients with ALL, we find that, despite a generally low...
10.
Gbadamosi M, Shastri V, H Elsayed A, Ries R, Olabige O, Nguyen N, et al.
Leukemia . 2022 Jun; 36(8):2022-2031. PMID: 35688939
Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody linked to calicheamicin, a DNA damaging agent, and is a well-established therapeutic for treating acute myeloid leukemia (AML). In this study, we...